MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer
MMP9(而非EGFR、MET、ERCC1、P16和P-53)与局部晚期头颈癌患者接受同步放疗、西妥昔单抗和每周顺铂治疗的疗效相关。
期刊:Journal of Oncology
影响因子:
doi:10.1155/2009/305908
Fountzilas, George; Kalogera-Fountzila, Anna; Lambaki, Sophia; Wirtz, Ralph M; Nikolaou, Angelos; Karayannopoulou, Georgia; Bobos, Mattheos; Kotoula, Vassiliki; Murray, Samuel; Lambropoulos, Alexandros; Aravantinos, Gerasimos; Markou, Konstantinos; Athanassiou, Eleni; Misailidou, Despina; Kalogeras, Konstantine T; Skarlos, Demosthenis
肿瘤
RCC1
ERCC1
多发性骨髓瘤
肿瘤免疫
EGF
EGFR
头颈癌
MMP9
MET